Short Interest Runner: Is T2 Biosystems Incorporated (NASDAQ:TTOO) a Buy? The Stock Reported more Sellers

November 18, 2016 - By Hazel Jackson   ·   0 Comments

Short Interest Runner: Is T2 Biosystems Incorporated (NASDAQ:TTOO) a Buy? The Stock Reported more Sellers

The stock of T2 Biosystems Incorporated (NASDAQ:TTOO) registered an increase of 2.23% in short interest. TTOO’s total short interest was 2.43 million shares in November as published by FINRA. Its up 2.23% from 2.38 million shares, reported previously. With 70,900 shares average volume, it will take short sellers 34 days to cover their TTOO’s short positions. The short interest to T2 Biosystems Incorporated’s float is 20.24%. About 1,378 shares traded hands. T2 Biosystems Inc (NASDAQ:TTOO) has declined 33.70% since April 18, 2016 and is downtrending. It has underperformed by 38.13% the S&P500.

T2 Biosystems, Inc. is an in vitro diagnostics firm engaged in developing a technology platform offering an alternative to diagnostic methodologies. The company has a market cap of $193.56 million. The Company’s T2 Magnetic Resonance platform enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). It currently has negative earnings. The Company’s initial development efforts target sepsis, hemostasis and Lyme disease.

T2 Biosystems Inc (NASDAQ:TTOO) Ratings Coverage

Out of 7 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. T2 Biosystems Inc has been the topic of 13 analyst reports since July 21, 2015 according to StockzIntelligence Inc. As per Sunday, August 16, the company rating was maintained by BTIG Research. The stock of T2 Biosystems Inc (NASDAQ:TTOO) has “Strong Buy” rating given on Wednesday, July 20 by WBB Securities. The rating was upgraded by BTIG Research on Thursday, September 3 to “Buy”. Canaccord Genuity initiated the shares of TTOO in a report on Tuesday, October 27 with “Buy” rating. The firm has “Buy” rating given on Wednesday, November 2 by Cantor Fitzgerald. The rating was reinitiated by Leerink Swann on Thursday, November 10 with “Market Perform”. The company was downgraded on Tuesday, April 12 by Janney Capital. The stock of T2 Biosystems Inc (NASDAQ:TTOO) earned “Neutral” rating by BTIG Research on Tuesday, July 21. The firm earned “Buy” rating on Tuesday, August 2 by Canaccord Genuity.

TTOO Company Profile

T2 Biosystems, Inc., incorporated on April 27, 2006, is an in vitro diagnostics firm that is engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Firm is focused on developing and launching commercially its diagnostic products aimed at reducing mortality rates, improving patient outcomes and reducing the cost of healthcare. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance approach that measures how water molecules react in the presence of magnetic fields. The Company’s platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements.

More important recent T2 Biosystems Inc (NASDAQ:TTOO) news were published by: Prnewswire.com which released: “Canon U.S.A. Announces Equity Investment in T2 Biosystems, Inc.” on September 22, 2016, also Marketwatch.com published article titled: “T2 Biosystems stock price target cut to $11 from $13 at Leerink Partners”, Quotes.Wsj.com published: “News T2 Biosystems Inc.TTOO” on August 01, 2014. More interesting news about T2 Biosystems Inc (NASDAQ:TTOO) was released by: Streetinsider.com and their article: “Leerink Partners Resumes T2 Biosystems, Inc (TTOO) at Market Perform” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>